Hospitalizations From Veno-Occlusive Disease in the US Pacific Region: A Six-Cohort Analysis of National In-Patient Data (2016-2020)

Speaker(s)

Aggarwal S1, Kumar S2, Topaloglu O3
1NOVEL Health Strategies, Chevy Chase, MD, USA, 2NOVEL HEALTH STRATEGIES, COLUMBIA, MD, USA, 3NOVEL Health Strategies, Bethesda, MD, USA

OBJECTIVES: To evaluate the burden of hospitalizations due to Veno-Occlusive Disease (VOD/SOS) in the US Pacific region using pooled national inpatient data from 2016 to 2020.

METHODS: The 2016-2020 National Inpatient Sample (NIS) datasets were pooled and analyzed for hospitalizations due to VOD in the US Pacific region. Six cohorts were created: (1) all hospitalizations, (2) hospitalizations above the 90th percentile by charges, (3) hospitalizations below the 90th percentile by charges, (4) hospitalizations above the 90th percentile by comorbidity score, (5) hospitalizations below the 90th percentile by comorbidity score, and (6) in-hospital deaths. Comorbidity rates were assessed using the Charlson Index, the Elixhauser Method, and broad ICD-10 categories.

RESULTS: From 2016 to 2020, there were an estimated 340 VOD-related hospitalizations in the US Pacific region. For the six cohorts, the mean ages were 23.68 (SD 23.19), 11.5 (SD 10.41), 24.85 (SD 23.79), 53.67 (SD 44.52), 22.29 (SD 21.38), and 34.43 (SD 22.23) years, respectively. The mean hospital length of stay (LOS) was 36.65 (SD 36.94), 121.17 (SD 30.48), 28.47 (SD 25.53), 16.67 (SD 24.54), 37.57 (SD 37.28), and 73 (SD 46.74) days, respectively. The mean total charges were $1,241,210 (SD 1,574,159), $4,927,810 (SD 2,059,532), $884,442 (SD 952,807), $567,430 (SD 816,964), $1,272,308 (SD 1,597,188), and $2,427,505 (SD 1,272,600), respectively. The mortality rate in the 90th percentile by charges cohort was 33.3%. The comorbidity scores were 3.72 (SD 1.57), 3.17 (SD 1.33), 3.77 (SD 1.59), 7.0 (SD 0), 3.57 (SD 1.44), and 3.29 (SD 1.5), respectively. The top non-VOD principal diagnoses were acute lymphoblastic leukemia not in remission, malignant neoplasm of unspecified part of the unspecified adrenal gland, and nodular sclerosis Hodgkin lymphoma, unspecified site.

CONCLUSIONS: The analysis of pooled five-year real-world hospital records of VOD in the US Pacific region indicates a significant clinical and economic burden posed by these patients.

Code

EE325

Topic

Economic Evaluation

Disease

Cardiovascular Disorders (including MI, Stroke, Circulatory), Rare & Orphan Diseases